PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on...
Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with...
Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4CAMBRIDGE, Mass., May 01, 2021...
Analytical assessment demonstrates structural, physicochemical, and biological similarity between SB11 and Lucentis SB11 is under review by the FDA and...
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual...
CHICAGO, April 30, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform...
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 30, 2021 (GLOBE NEWSWIRE)...